piperacillin + tazobactam + voriconazole

This is a combination therapy consisting of piperacillin, tazobactam, and voriconazole. Piperacillin is an extended-spectrum penicillin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Tazobactam is a beta-lactamase inhibitor that protects piperacillin from enzymatic degradation by beta-lactamase-producing bacteria, thereby extending its antibacterial spectrum. Voriconazole is a second-generation triazole antifungal agent that inhibits fungal ergosterol synthesis by blocking the enzyme lanosterol 14-alpha-demethylase (CYP51), disrupting fungal cell membrane formation and function. This combination may be used in immunocompromised patients or those at high risk for both severe bacterial and invasive fungal infections, such as neutropenic cancer patients. The drugs are administered intravenously.